BMY Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 0.58% compared to Bristol-Myers Squibb's net margin of 23.56%. Bristol-Myers Squibb's return on equity of -46.27% beat Gilead Sciences's return on equity of 2.5%.

Bristol-Myers Squibb has a consensus price target of $61.24, signalling upside risk potential of 3.79%. On the other hand Gilead Sciences has an analysts' consensus of $111.26 which suggests that it could fall by -0.16%. Given that Bristol-Myers Squibb has higher upside potential than Gilead Sciences, analysts believe Bristol-Myers Squibb is more attractive than Gilead Sciences.

Bristol-Myers Squibb has a beta of 0.435, which suggesting that the stock is 56.528% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.213, suggesting its less volatile than the S&P 500 by 78.702%.

Bristol-Myers Squibb has a quarterly dividend of $0.62 per share corresponding to a yield of 4.1%. Gilead Sciences offers a yield of 2.78% to investors and pays a quarterly dividend of $0.79 per share. Bristol-Myers Squibb pays -54.35% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Bristol-Myers Squibb quarterly revenues are $12.3B, which are larger than Gilead Sciences quarterly revenues of $7.6B. Bristol-Myers Squibb's net income of $72M is lower than Gilead Sciences's net income of $1.8B. Notably, Bristol-Myers Squibb's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 301.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.48x versus 4.87x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 0.58% compared to Bristol-Myers Squibb's net margin of 32.59%. Bristol-Myers Squibb's return on equity of -46.27% beat Eli Lilly and's return on equity of 80.24%.

Bristol-Myers Squibb has a consensus price target of $61.24, signalling upside risk potential of 3.79%. On the other hand Eli Lilly and has an analysts' consensus of $1,006.63 which suggests that it could grow by 23.74%. Given that Eli Lilly and has higher upside potential than Bristol-Myers Squibb, analysts believe Eli Lilly and is more attractive than Bristol-Myers Squibb.

Bristol-Myers Squibb has a beta of 0.435, which suggesting that the stock is 56.528% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

Bristol-Myers Squibb has a quarterly dividend of $0.62 per share corresponding to a yield of 4.1%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Bristol-Myers Squibb pays -54.35% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bristol-Myers Squibb quarterly revenues are $12.3B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Bristol-Myers Squibb's net income of $72M is lower than Eli Lilly and's net income of $4.4B. Notably, Bristol-Myers Squibb's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 69.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.48x versus 16.33x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 0.58% compared to Bristol-Myers Squibb's net margin of 23.96%. Bristol-Myers Squibb's return on equity of -46.27% beat Merck &'s return on equity of 40.25%.

Bristol-Myers Squibb has a consensus price target of $61.24, signalling upside risk potential of 3.79%. On the other hand Merck & has an analysts' consensus of $112.29 which suggests that it could grow by 18.73%. Given that Merck & has higher upside potential than Bristol-Myers Squibb, analysts believe Merck & is more attractive than Bristol-Myers Squibb.

Bristol-Myers Squibb has a beta of 0.435, which suggesting that the stock is 56.528% less volatile than S&P 500. In comparison Merck & has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.24%.

Bristol-Myers Squibb has a quarterly dividend of $0.62 per share corresponding to a yield of 4.1%. Merck & offers a yield of 3.3% to investors and pays a quarterly dividend of $0.81 per share. Bristol-Myers Squibb pays -54.35% of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bristol-Myers Squibb quarterly revenues are $12.3B, which are smaller than Merck & quarterly revenues of $15.6B. Bristol-Myers Squibb's net income of $72M is lower than Merck &'s net income of $3.7B. Notably, Bristol-Myers Squibb's price-to-earnings ratio is -- while Merck &'s PE ratio is 14.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.48x versus 3.74x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 0.58% compared to Bristol-Myers Squibb's net margin of 2.31%. Bristol-Myers Squibb's return on equity of -46.27% beat Pfizer's return on equity of 8.91%.

Bristol-Myers Squibb has a consensus price target of $61.24, signalling upside risk potential of 3.79%. On the other hand Pfizer has an analysts' consensus of $31.32 which suggests that it could grow by 21.76%. Given that Pfizer has higher upside potential than Bristol-Myers Squibb, analysts believe Pfizer is more attractive than Bristol-Myers Squibb.

Bristol-Myers Squibb has a beta of 0.435, which suggesting that the stock is 56.528% less volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

Bristol-Myers Squibb has a quarterly dividend of $0.62 per share corresponding to a yield of 4.1%. Pfizer offers a yield of 6.57% to investors and pays a quarterly dividend of $0.43 per share. Bristol-Myers Squibb pays -54.35% of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Bristol-Myers Squibb quarterly revenues are $12.3B, which are smaller than Pfizer quarterly revenues of $17.8B. Bristol-Myers Squibb's net income of $72M is lower than Pfizer's net income of $410M. Notably, Bristol-Myers Squibb's price-to-earnings ratio is -- while Pfizer's PE ratio is 18.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol-Myers Squibb is 2.48x versus 2.30x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.